New MD, Unproven Recovery, Market Already Priced Out the Hope
Q1 revenue slumped 27%, profit fell 70%, and disbursement came in at just ₹117 Cr against a ₹1,000–1,200 Cr target. Management blames transition and claims Q2 recovery is already here. The street remains unconvinced.
₹103.3 Cr
-27.2% YoY
₹40.2 Cr
-70.5% YoY
4.46%
vs. 3.5–4.0% target
3.31% / 5.19%
low despite NIM strength
PTC India's Q1 looks like a study in misalignment. On the surface: revenue fell 27% year-on-year to ₹103.3 Cr, profit crashed 70% to ₹40.2 Cr. On the margin front: net interest margin held a strong 4.46%, above the 3.5–4.0% guidance band. The paradox is stark — the lending margin is healthy, but the lending book is shrinking faster than the company can grow it. That is the quarter.
The Q1 disbursement miss that started it all
In prior FY-2026 calls, management guided for a "significant acceleration" in Q4 FY'26, targeting ₹1,000–1,200 crore quarterly disbursements and ~15% sequential AUM growth. This quarter, actual disbursements came to ₹117 Cr — a 90% miss on the prior aspiration. The reason: a new MD took charge mid-quarter and decided to recalibrate. New MD Rajiv Malhotra inherited what he described on the call as a portfolio needing 'recalibration.' Infrastructure lending got refocused; the FI and SME books were put on pause. But the reset meant Q1 was always going to look weak.
What management is betting on now: Q2 is already here, and sanctions of >₹1,200 Cr have been approved — a record 13-quarter monthly pace. If those convert to disbursal in the coming weeks, the narrative flips. If they don't, it's proof that the prior MD wasn't wrong about the challenges, and the new MD inherited a book where the problem isn't strategy — it's execution.
Management claims vs. reality: what holds
Disbursements reflect calibrated portfolio consolidation
₹117 Cr vs. ₹1,000–1,200 Cr prior target (90% miss)
Supported by transition, but credibility depends on Q2 realization
NIM healthy at 4.46%, suggesting strong asset quality
NIM confirmed at 4.46%; but ROA 3.31%, RONW 5.19% are low, pointing to high fixed costs
Partially supported — NIM is real, but quality doesn't explain the low returns
Asset quality stable; NPA not a broad deterioration
Gross Stage III ₹190 Cr (6.4% of assets); ₹187 Cr (98.4%) in ONE legacy NCLT account
Supported — the bad news is isolated, not systemic
Q2 sanctions >₹1,200 Cr (record 13-quarter) signal momentum
Confirmed; but sanctions ≠ disbursals. Conversion depends on borrower capex milestones, project delays cited
Overstated on confidence — it's a leading indicator, not proof
Positioned for stronger growth trajectory going forward
Track record poor (revenue -27%, PAT -70%); recovery unproven; depends on Q2-Q4 execution by new MD
Contradicted — it's a hope, not a demonstrated trajectory
What changed on this call
Three material shifts:
Leadership transition, not announcement. New MD Rajiv Malhotra took charge mid-Q1. Prior MD exited (reason not disclosed). The reset created Q1 weakness and is now justifying the pivot to infrastructure focus and pause on FI/SME lending.
Disbursement guidance downgraded to AUM guidance. Prior call: ₹1,000–1,200 Cr quarterly disbursement run-rate. This call: ₹5,000 Cr AUM by FY27-end (implies ~1,000–1,200 Cr average over 9 months, a weaker commitment). The shift from a near-term metric to a year-end target signals lower confidence in near-term delivery.
NPA composition clarity: one account, not many. Prior calls implied ongoing broad NPA deterioration. This call isolates ₹187 Cr (98.4% of ₹190 Cr Gross Stage III) in ONE legacy account, NCLT-pending. Binary outcome, not tail risk.
The bull case vs. the bear case
NIM healthy (4.46%), above guidance; credit quality real
Infrastructure focus aligned with India's 10–20 year capex cycle
Q2 sanctions (>₹1,200 Cr) signal management conviction
NPA isolated to one legacy NCLT account (not systemic)
Strong capital base (₹3,120 Cr NW); excess capital available for growth
Revenue -27% YoY; PAT -70% YoY — volume collapse dominates
Disbursement miss (₹117 Cr vs. ₹1,000–1,200 Cr target) is 90% below aspiration
New MD unproven; asks for 2–3 quarters without specific milestones
Sanction-to-disbursal gap is real (project delays, borrower capex milestones)
Cost of funds unresolved; new lending facilities not yet sanctioned
Retail investor pushback on 3–4 year track record; no dividend visibility
Stock down 31% from ATH, RSI oversold (12.6), but day-1 -3.47% reaction held
Risks, ranked by how much they should concern a holder
NPA concentration: ₹187 Cr (98.4% of ₹190 Cr Gross Stage III) in ONE legacy NCLT-pending account
HighBinary outcome risk. If NCLT rejects admission or valuation is low, material loss to equity. The queue for NCLT resolution is long; timing uncertain. Resolved only post-admission process, expected Q1 FY27 (but no guarantee).
Sanction-to-disbursal gap: >₹1,200 Cr sanctioned in Q2 but not yet disbursed
HighConversion depends on borrower construction milestones. Oil/gas projects cited as delayed due to commodity/geopolitical factors. If >50% of Q2 sanctions fail to convert by Q3, recovery narrative collapses and new MD credibility takes a hit.
Execution track record: new MD unproven; prior MD also missed targets
HighThe entire bull case hinges on Q2-Q4 execution by a first-time caller (new MD). No track record to point to. Prior MD also claimed growth and underwhelmed. Street is wait-and-see; profit-taking if Q2 doesn't deliver.
Cost of funds: high borrowing cost vs. asset yields; new facility sanctions pending
MediumNIM 4.46% is solid, but margin sustainability depends on cost reduction. New facilities not yet sanctioned (expected end Q2). If cost doesn't improve, near-term ROA/RONW pressure persists despite AUM growth.
Balance-sheet shrinkage: loan assets ₹2,946 Cr (organic decline QoQ)
MediumLow Q1 disbursal (₹117 Cr) likely masked by repayments. AUM target of ₹5,000 Cr by FY27-end requires 70% growth in 9 months — aggressive and execution-dependent. If sanctions don't convert, book shrinkage continues.
Macro headwinds: oil/gas project construction delays; commodity/geopolitical cycle exposure
MediumPrimary loan book exposure is infrastructure (oil/gas, power, etc.). Delay in one sector delays loan conversion. No hedging or offset described.
How the street is positioned (and what the market's own verdict is)
Price action & drawdown. The stock closed the day before result announcement at ₹28.78. On day 1 post-result, it fell 3.47%; by day 3, it was down 3.93% cumulatively. The sell-off did not reverse, which is the street's own verdict: the weak numbers and reset narrative were expected. No relief rally happened, and the stock is now at ₹27.65, down 31.73% from its all-time high of ₹40.5. Below SMA20, SMA50, and SMA200 — the technical backdrop is bearish.
Valuation & opportunity context. RSI stands at 12.6 (oversold territory), suggesting the selloff may be near-term extreme. The 52-week range is ₹23.85–₹40.5; the current price is 15.93% off the low but still 31.73% below ATH. For a recovery narrative to work, the stock needs proof of Q2 execution, not just management intent.
Ownership & flows. FII holding stable at 2.13% (down 0.04pp QoQ), DII at 5.05% (down 0.01pp). Promoter holding flat at 64.99%. No large block trades reported. The lack of institutional buying into this weakness is telling — the recovery is priced in at the discount, but confidence is low. Retail investors on the call were vocal and skeptical ('multi-year zero capital return,' 'why stay invested'); management's response was defensive ('give us 2–3 quarters').
What to watch next
1 · Q2 disbursal realization from >₹1,200 Cr sanctions (Sep 2026)
The lynchpin. If >₹800 Cr (67%) converts to actual disbursal, recovery narrative survives. If <₹500 Cr, new MD's credibility is tested, and stock reprices lower. Watch for commentary on project delays in oil/gas, borrower construction timelines.
2 · NCLT admission & resolution process for ₹187 Cr legacy NPA (Sep 2026+)
Application is pending admission. Once admitted, the IBC process begins. Resolution timeline is 18–24 months typical, but equity recovery is uncertain. Update on timeline and recovery assumption will be key to Q2 call.
3 · New lending facility sanctions & cost of funds trajectory (end Q2)
Management flagged pending new facility sanctions from multiple lenders by end Q2. Cost reduction is critical to sustaining NIM and improving ROA/RONW. Watch for quantum of new facilities and cost reduction (bps) achieved.
4 · AUM progress toward ₹5,000 Cr by FY27-end (visibility by Dec 2026)
Target requires 70% growth from ₹2,946 Cr in 9 months (~₹280–300 Cr monthly average disbursal). By H2 call (Dec 2026), halfway to target should be visible. If on track, bull case gains traction. If lagging, turnaround timeline extends.
The honest read
This is not a step-change recovery story — it is an execution turnaround. Q1 was intentionally weak (new MD reset), and Q2 will test whether the reset was justified or a mistake. The bull case has merit (infrastructure is a real 10–20 year India tailwind, NPA is isolated, capital is strong), but the new MD has zero track record and zero credibility with the street. Management's ask for '2–3 quarters' is fair, but no patience remains — the stock has already repriced -31% from ATH.
The market's verdict is clear: 'Prove it in Q2.' RSI oversold (12.6) suggests near-term consolidation, but until disbursement realization is visible, institutional buying is unlikely. Retail investors on the call were burned by three years of poor returns and no dividend; they are skeptical, not hopeful.
The number to track from here is Q2 disbursal realization. If >₹800 Cr of the >₹1,200 Cr sanctions convert to actual disbursal, the turnaround is real, and the stock has room to re-rate. If <₹500 Cr, the problem is deeper than strategy, and the new MD will have to reset again. That binary is where the risk sits.
Informational and educational content only. Not investment advice.